471 related articles for article (PubMed ID: 17097724)
21. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.
Csomor PA; Stadler RR; Feldon J; Yee BK; Geyer MA; Vollenweider FX
Neuropsychopharmacology; 2008 Feb; 33(3):497-512. PubMed ID: 17460616
[TBL] [Abstract][Full Text] [Related]
22. Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Hudson MR; Rind G; O'Brien TJ; Jones NC
Transl Psychiatry; 2016 Apr; 6(4):e784. PubMed ID: 27093066
[TBL] [Abstract][Full Text] [Related]
23. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs.
Dirks A; Groenink L; Westphal KG; Olivier JD; Verdouw PM; van der Gugten J; Geyer MA; Olivier B
Neuropsychopharmacology; 2003 Oct; 28(10):1790-8. PubMed ID: 12865891
[TBL] [Abstract][Full Text] [Related]
24. Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs.
Egashira N; Tanoue A; Higashihara F; Fuchigami H; Sano K; Mishima K; Fukue Y; Nagai H; Takano Y; Tsujimoto G; Stemmelin J; Griebel G; Iwasaki K; Ikeda T; Nishimura R; Fujiwara M
Neuropsychopharmacology; 2005 Nov; 30(11):1996-2005. PubMed ID: 15956991
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism.
Duncan GE; Miyamoto S; Leipzig JN; Lieberman JA
J Pharmacol Exp Ther; 2000 Apr; 293(1):8-14. PubMed ID: 10734147
[TBL] [Abstract][Full Text] [Related]
26. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Le Pen G; Moreau JL
Neuropsychopharmacology; 2002 Jul; 27(1):1-11. PubMed ID: 12062902
[TBL] [Abstract][Full Text] [Related]
27. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function.
Moy SS; Perez A; Koller BH; Duncan GE
Brain Res; 2006 May; 1089(1):186-94. PubMed ID: 16638606
[TBL] [Abstract][Full Text] [Related]
28. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics.
Zhang W; Pouzet B; Jongen-Rêlo AL; Weiner I; Feldon J
Neuroreport; 1999 Aug; 10(12):2533-8. PubMed ID: 10574365
[TBL] [Abstract][Full Text] [Related]
29. Detrimental effect of postnatal blockade of N-methyl-D-aspartate receptors on sensorimotor gating is reversed by neuroleptic drugs.
Wedzony K; Fijał K; Maćkowiak M; Chocyk A
Pharmacol Rep; 2008; 60(6):856-64. PubMed ID: 19211977
[TBL] [Abstract][Full Text] [Related]
30. Hyperactivity and disruption of prepulse inhibition induced by N-methyl-D-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine.
Bast T; Zhang WN; Heidbreder C; Feldon J
Neuroscience; 2001; 103(2):325-35. PubMed ID: 11246148
[TBL] [Abstract][Full Text] [Related]
31. Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice.
Furuya Y; Kagaya T; Ogura H; Nishizawa Y
Eur J Pharmacol; 1999 Jan; 364(2-3):133-40. PubMed ID: 9932715
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of the strychnine-insensitive glycine site antagonist (+)-HA-966 on the hyperactivity and the disruption of prepulse inhibition induced by phencyclidine in rats.
Furuya Y; Kagaya T; Nishizawa Y; Ogura H
Brain Res; 1998 Jan; 781(1-2):227-35. PubMed ID: 9507144
[TBL] [Abstract][Full Text] [Related]
33. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats.
Bast T; Zhang W; Feldon J; White IM
Pharmacol Biochem Behav; 2000 Nov; 67(3):647-58. PubMed ID: 11164097
[TBL] [Abstract][Full Text] [Related]
34. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.
Kumari V; Antonova E; Geyer MA; Ffytche D; Williams SC; Sharma T
Int J Neuropsychopharmacol; 2007 Aug; 10(4):463-77. PubMed ID: 16923324
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.
Geyer MA; Krebs-Thomson K; Braff DL; Swerdlow NR
Psychopharmacology (Berl); 2001 Jul; 156(2-3):117-54. PubMed ID: 11549216
[TBL] [Abstract][Full Text] [Related]
36. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition.
McCaughran J; Mahjubi E; Decena E; Hitzemann R
Psychopharmacology (Berl); 1997 Nov; 134(2):131-9. PubMed ID: 9399376
[TBL] [Abstract][Full Text] [Related]
37. Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.
Thomsen M; Wörtwein G; Fink-Jensen A; Woldbye DP; Wess J; Caine SB
Psychopharmacology (Berl); 2007 May; 192(1):97-110. PubMed ID: 17310388
[TBL] [Abstract][Full Text] [Related]
38. Startle and sensorimotor gating in rats lacking CCK-A receptors.
Feifel D; Priebe K; Shilling PD
Neuropsychopharmacology; 2001 Jun; 24(6):663-70. PubMed ID: 11331146
[TBL] [Abstract][Full Text] [Related]
39. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
40. Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.
Bortolato M; Frau R; Orrù M; Piras AP; Fà M; Tuveri A; Puligheddu M; Gessa GL; Castelli MP; Mereu G; Marrosu F
Psychopharmacology (Berl); 2007 Oct; 194(3):361-9. PubMed ID: 17604981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
